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were on polytherapy, 41% on monotherapy, and 4% had no antihypertensive treat-
ment. Polytherapy was more predominant with age, duration of diabetes, duration of 
hypertension, and comorbid complications. ConClusions: Although prescribing 
pattern of antihypertensive showed adherence to existing evidence-based guide-
lines, higher proportion of uncontrolled hypertensive patients was found.
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objeCtives: Patients undergoing initial therapeutic anticoagulation after a venous 
thromboembolic event (VTE) with severely impaired renal function (RI-VTE-patients) 
are at high risk of accumulating the anticoagulants resulting in an increased risk of 
bleeding events. Current guidelines/approved summary of product characteristics 
(SPC) recommend usage of specific anticoagulants only, monitoring of aXa-activity, 
and/or dose-adjustment (in the case of enoxaparin) for initial therapeutic anticoagu-
lation of RI-VTE-patients. This study investigates the treatment of German RI-VTE-
patients and evaluates whether guideline/SPC recommendations are implemented 
in the practice of real life care. Methods: We conducted a chart review in 5 German 
hospitals. All VTE patients treated in these hospitals from 01/01/2007-31/12/2011 
were included. RI was defined as CrCl< 30ml/min. Treatment did not conform to the 
recommendations in guidelines/SPCs, if: a) A drug was used that is contraindicated 
according to the SPC; b) The recorded daily dose of enoxaparin was higher than the 
recommended weight-adjusted dose. Results: Of 5,263 VTE patients identified, 709 
(13.5%) cases could not be documented due to missing charts (601) or no documented 
creatinine serum levels (108). Of the remaining 4,554 patients (mean age ±SD 67.4 
years ±15.7; 53.0% female; weight 80.2 kg ±20.0; 54.5% deep VT), 337 (7.4%) had a mean 
estimated GFR< 30ml/min; additionally 1,630 (35.8%) had a minimum eGFR< 60ml/
min. In 19 (5.6%) of these cases, patients were treated with a drug not recommended 
for use, 21 (6.2%) did not receive any initial anticoagulation treatment and 91 (27.0%) 
received a higher than recommended dosage of enoxaparin. Additionally, for 22 
patients (6.5%) receiving enoxaparin, no weight information was recorded and it 
is therefore unlikely that the dosage was adjusted correctly. ConClusions: VTE 
treatment in RI-VTE-patients differs remarkably from labelled recommendations; 
over-dosage of enoxaparin is common. It seems fair to assume that these patients are 
facing a higher risk of adverse reactions in particular bleeding events.
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objeCtives: To determine the attitude of physicians in three family medicine centers 
(FMCs) at the National Guard Health Affairs (NGHA) toward the implementation of 
the Shared Medical Appointment (SMA) approach compared to the current individual 
appointment approach. Methods: A cross-sectional survey study was conducted 
by distributing a structured questionnaire among the 79 FMCs’ physicians at NGHA 
in Riyadh, Saudi Arabia. The first part of the questionnaire was an introduction, the 
second part has requested socio-demographic information, and the third part con-
sisted of 12 statements measuring physicians’ attitude toward implementing SMA 
and the current individual appointment approach. Responses were measured using 
5-points Likert Scale. Seventy-nine self-administered questionnaires were distributed 
to physicians’ mail-boxes and the completed questionnaires were collected from 
mail-boxes at each clinic. Data collection was done from December 10 to 15, 2011. 
Data were entered and analyzed by the Statistical Package for Social Science (SPSS.16). 
Descriptive analysis was conducted using frequencies, percentages, and mean (SD). 
Inferential analysis was conducted using one way ANOVA and Mann-Whitney tests 
to detect statistically significant differences in responses. A significance level of 
0.05 was used. The validity and reliability of the instrument was measured using 
Pearson’s correlation and Cronbach’s Alpha, respectively. Results: A totla of 78 valid 
questionnaires were returned yielding a response rate of 99 %. The average attitude 
scores were 3.75 toward the SMA approach and 2.98 toward the current Individual 
Appointment approach. The average attitude scores were significantly different at all 
dimensions (Mann Whtiney P-value < 0.001) in favor of SMA except for patient privacy 
which was in favor of current individual appointment approach. Subgroup analysis by 
socio-demographic variables indicated that males and Saudi national physicians have 
higher positive attitude toward SMA. ConClusions: There is positive attitude of all 
physicians toward SMA compared to the current individual appointment approach. 
This attitude was affected by gender and nationality.
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objeCtives: To assess the re-hospitalisations rates for stroke (ST) and transient 
ischemia (TI) recurrences as well as related inpatient costs through the French 
national Hospitals Medical Health Information database (PMSI). Methods: A ret-
rospective hospital administrative-claims analysis was carried out based on the 
Diagnoses Related Groups (DRG)-data of four hospitals within the Burgundy region 
along the 2006-2011 period. In each of the four hospitals, three cohorts were fol-
lowed up over two years. Patients were excluded if any related hospitalisation for ST 
or TI occurred in the preceding two-years (identification through ICD-10 diagnosis 
codes). One and two-year re-hospitalisations rates for ST and/or IT were calculated. 
guidelines, health prevention / monitoring strategies, involving coordinated actions 
between primary care and pharmacies, are valuable resources to consider.
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objeCtives: The Ukrainian government has been considering ways to improve the 
population’s access to medicines by offering limited reimbursement access. For this 
purpose, the government has expressed its interest in implementing International 
reference pricing (IRP). The pilot hypertension programme, which introduced a sys-
tem of IRP for certain hypertension drugs, was introduced in mid-2012. The govern-
ment is currently looking to revise the pricing and reimbursement mechanism and 
to expand the list of drugs eligible for reimbursement under the scheme. This study 
examines the pilot hypertension programme and its impact in terms of achieving its 
objectives so far. Methods: Secondary research focused on analysing the current 
pharmaceutical market and health care situation in Ukraine, with a specific focus on 
the hypertension market. The study then assessed the pricing and reimbursement 
methodology which is currently in place, the programme’s objectives, and its impact 
on volume and value of the antihypertensives market. Results: Hypertension 
was chosen for the pilot programme due to the high prevalence of the condition in 
the country. While, for the full year 2012, the weighted average cost per package in 
the antihypertensive drug segment decreased by 1.4% compared to the previous 
year, the volume of retail sales increased 16.8%. Furthermore, as of January 2013, 
the prices of these drugs had been falling every month from July till December 
2012 compared to the corresponding months of 2011. ConClusions: With the 
pilot hypertension programme, the government is hoping to lower drug prices and 
thereby improve affordability. Considering that the pilot scheme could be followed 
by programmes in other therapeutic areas, including a government proposal to 
include IRP for insulin treatments, the structure and effectiveness of the hyperten-
sion programme, and the subsequent amendments to it, could substantially impact 
the development of any other potential programmes in the future.
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objeCtives: This paper constitutes an attempt at investigating processes of 
dynamic competition in pharmaceuticals, with reference to the nature and intensity 
of price competition in relation to patent expiry and different regulatory regimes. 
The paper uses comprehensive data on a selection of in-patent and off-patent 
(generic) cardiovascular medicines from IMS from the five largest European phar-
maceutical markets - UK, Germany, France, Italy, Spain - to analyze the impact that 
pricing and reimbursement regulation and product differentiation have on market 
structure, diffusion and prices. Methods: The paper develops a panel data model 
to explain the determinants of brand-name prices and generic prices both before 
and after patent expiry, the impact of generic entry and generic penetration on 
market share and prices of brand-name drugs, the competition patterns in their 
off-patent sector, the determinants of generic diffusion in the presence of generic 
competition, and the relationship between originator branded and generic prices 
under different regulatory regimes. The structure of the data allows these ques-
tions to be explored at molecule level and at product level. At all levels the origi-
nator and generic markets are observable. Results: Despite the proliferation of 
generic policies in many countries, prices in the off-patent sector do not decline as 
fast as originally thought. Entry into the generic market is positively influenced by 
regulation through reference pricing and opportunities for product differentiation. 
Elements of product differentiation within generics promote diffusion, but do not 
reduce prices. And, health insurance does not capitalize fully on the cost advantage 
of generic medicines. ConClusions: The results suggest that the relationships 
between the dynamics of original drug prices, patent expiry, and generic competi-
tion are complex and differentiated across countries. The level of generic penetra-
tion remains low in some of them and a sharp contrast exists between countries.
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objeCtives: Hypertension management is of a paramount importance in diabetic 
patients for cardiovascular risk reduction. Hence, we evaluated prescribing pattern 
of antihypertensive in T2DM (type 2 diabetes) patients and compare with existing 
recent guidelines. Methods: A cross-sectional study involving evaluation of all 
T2DM patients referred to endocrinology unit at tertiary care centre for hyperten-
sion, comorbid complications, and recording prescription. Utilization of 5 different 
antihypertensive drug classes was compared for all patients receiving 1, 2, 3, 4, or 
more drugs. Logistical regression was used to assess likelihood of prescription of 
drugs and/or therapy for specific conditions mentioned in the guidelines. Results: 
Out of 1358, T2DM enrolled patients 1186 (87%) had hypertension (males 52%, 
females 48%). The median duration (IQ) of hypertension diabetics was 4 (1-10) years. 
A total of 25% patients had controlled BP and 75% with uncontrolled blood pressure 
(13% isolated systolic hypertension, 6% isolated diastolic hypertension, and 55% 
both elevated). Overall, ACE inhibitors (ACEIs) were prescribed the highest (59%) 
followed by angiotensin receptor blockers (ARBs) (52%), calcium channel blockers 
(CCBs) (29%), diuretics (27%), and beta-blockers (14%). Overall, 55% of T2DM patients 
